Evaxion Biotech A/S January 2025 SEC Filing: Capital Increase & Warrant Exercise Insights

Here are the key insights extracted from the provided section of the financial report:

1. Filing Information:

• This is a Form 6-K filed with the SEC by Evaxion Biotech A/S.
• The report pertains to the month of January 2025.
• The Commission File Number is 001-39950.

2. Company Details:

• Name: Evaxion Biotech A/S
• Address: Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

3. Share Capital Increase:

• The company has registered an increase in its share capital by a total of DKK 11,470,000 ordinary shares.
• This increase is effective as of December 26 and 27, 2024.
• The total nominal share capital after this increase is DKK 70,130,556.

4. Warrant Exercise:

• The share capital increase is associated with the exercise of pre-funded warrants at an exercise price of $1.4537 per American Depositary Share (ADS).
• Each ADS represents ten ordinary shares.
• There remain prefunded warrants that allow the subscription of 851,000 ADSs at the same exercise price of $1.4537.

5. Amendment to Articles of Association:

• The Articles of Association have been amended to reflect the capital increase, effective on the same dates as the share capital increase.

6. Incorporation by Reference:

• The report will be incorporated by reference into various registration statements (Form S-8 and Form F-3, among others).

7. Signature:

• The report is signed by Christian Kanstrup, the Chief Executive Officer, dated January 7, 2025.

This information indicates that Evaxion Biotech A/S is actively managing its capital structure, likely to support growth initiatives or operational needs through the capital raised by the exercise of warrants. The details regarding the amendments to the Articles of Association show compliance with regulatory requirements concerning changes in capital.